Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
| ▸ | RBP4 | P02753 | 4/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095874 | 0.88 | NR1H4 (0.42) | NR1H4L3MBTL1GRM2DHODHKCNJ5 | |
| SCHEMBL20833740 | 0.84 | NR1H4 (0.43) | NR1H4P2RX7RORCDHODHKCNJ5 | |
| SCHEMBL2772447 | 0.83 | NR1H4 (0.39) | NR1H4L3MBTL1GRM2DHODHKCNJ5 | |
| SCHEMBL20833875 | 0.82 | NR1H4 (0.38) | NR1H4DHODHKCNJ5KCNJ3 | |
| SCHEMBL27839489 | 0.79 | RBP4 (0.34) | RBP4L3MBTL1GRM2RORCHTR2C | |
| SCHEMBL3774518 | 0.78 | NR1H4 (0.39) | NR1H4P2RX7DHODHCCR1 | |
| SCHEMBL20833795 | 0.77 | NR1H4 (0.40) | NR1H4DHODH | |
| SCHEMBL2773589 | 0.77 | TP53 (0.40) | RBP4P2RX7L3MBTL1 | |
| SCHEMBL17839932 | 0.76 | NR1H4 (0.41) | NR1H4L3MBTL1GRM2KCNJ5KCNJ3 | |
| SCHEMBL19689518 | 0.75 | NR1H4 (0.47) | NR1H4KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101448791-B | Fxr agonists | LILLY CO ELI | 2011-11-16 | — | — | CN | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| CN-101448791-A | FXR agonists | LILLY CO ELI (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | NR1H4 1/4885RBP4 434/4885P2RX7 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.